MedTrace Logo

Vasopressin Effects on Human Social Communication

NCT01327027 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2017-11-06

No results posted yet for this study

Summary

This research is being done because we wish to understand how a chemical produced in the brain, vasopressin, effects emotional social communication processes. Understanding how this system works in normal individuals may help us understand why some people, particularly those with autism and/or antisocial personality disorder, have dysfunctional social interactions.

This study will test the effects of 3 doses of arginine vasopressin, delivered intranasally, on physiological and behavioral responses to the faces of same- and other-sex individuals in healthy men and women.

Conditions

  • Healthy

Interventions

DRUG

Vasopressin, Arginine, ADH

Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)

DRUG

Placebo; Sterile Saline

Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.

Sponsors & Collaborators

  • MaineHealth

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Bowdoin College

    lead OTHER

Principal Investigators

  • Richmond Thompson, Ph.D. · Bowdoin College

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2015-12-31
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327027 on ClinicalTrials.gov